ClinicalTrials.gg
Not yet recruitingNCT07947433Updated Nov 19, 2026

Effect of taVNS on Post-stroke Dysphagia

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation and Sham taVNS in Dysphagia Post Stroke, sponsored by Cairo University. Not yet recruiting. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Study summary

This study investigates the effect of transcutaneous auricular vagus nerve stimulation (taVNs) on dysphagia rehabilitation in sub-acute stroke patients.

Read the detailed description

This study investigates the effect of transcutaneous auricular vagus nerve stimulation (taVNs) on dysphagia rehabilitation in sub-acute stroke patients. Participants will be randomly assigned to conventional dysphagia rehabilitation with either true taVNS or a sham taVNS. Each patient will receive three sessions per week for four weeks. Each session will last 45 minutes, with taVNS on for 30 minutes during the session in the study group. Same goes for the control group with sham taVNS .

Swallowing function will be assessed by Fiberoptic-Endoscopic Evaluation Of Swallowing (FEES) before and after the intervention period.

02

Conditions studied

  • Dysphagia Post Stroke
03

In context

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 580 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Cairo University is the lead sponsor of 4,965 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. - Forty patients from both sexes with sub-acute ischemic or hemorrhagic stroke.
  2. - Dysphagia diagnosed by FEES and DOSS score 2-4.
  3. - The Patients age will be 45-70 years old. 4-Mini Mental scale examination score >25.

Exclusion criteria

Exclusion Criteria:

  1. Cognitive impairment that prevents participation in treatment.
  2. Structural impairments in the throat and esophagus.
  3. Dysphagia due to any other disease.
  4. Patients with severe cardiovascular problems (unstable angina, recent myocardial infarction within the last three months, congestive heart failure, significant heart valve dysfunction, or unstable hypertension).
  5. Patients with any taVNS e.g. previous surgical intervention on vagus nerve, facial or ear pain, recent ear trauma, metal implants above the level of the neck, pacemaker or other implanted electrical device.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Control group

    This group will receive conventional dysphagia rehabilitation consisting of exercises aimed at increasing the strength of supra-hyoid muscles and the pharyngeal constrictors. Thermal-tactile stimulation will also be applied. Alongside that , sham taVNS will be applied.

    Device: Sham taVNS

  • Experimental
    Study group

    This group will receive conventional dysphagia rehabilitation consisting of exercises aimed at increasing the strength of supra-hyoid muscles and the pharyngeal constrictors. Thermal-tactile stimulation will also be applied. Alongside that , true taVNS will be applied at 250μs , 25 HZ, and intensity to the patient's tolerance.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation

    taVNS with parameters set at 250 μs , 25 HZ, and current intensity to the patient's tolerance.

    Also known as: True taVNS

  • DeviceSham taVNS

    Sham taVNS

06

What researchers measure

Primary outcomes

  1. Penetration-Aspiration Scale (PAS) score

    Swallowing function will be assessed before and after intervention by comparing the patient's score on the Penetration-Aspiration Scale (PAS) as seen during Fiberoptic Endoscopic Examination Of Swallowing Function (FEES)

    Time frame: At enrollment and after 4 weeks of intervention

Secondary outcomes

  1. FOIS

    Functional oral intake scale

    Time frame: At enrollment and after 4 weeks of intervention

  2. Arabic EAT-10

    Arabic version of the eating assessment tool (EAT-10)

    Time frame: At enrollment and after 4 weeks of intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 290 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 3 months is below that.

Counting every sponsor, half of 299 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947433
Lead sponsor
Cairo University
Responsible party
Nour Maged Abdelmoez Hassan (Neurological Physical Therapist, Cairo University) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Nour Maged PT
Contact
nourmaged.998@gmail.com
+20 01144965933

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion